Rivastigmine Tartrate
Product Images NDC 75834-136

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 75834-136). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nivagen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Rivastigmine 01)

Chemical structure diagram of Rivastigmine Tartrate, showing the molecular arrangement including functional groups and the tartrate component indicated by .C4H6O6.*

FDA Label Image

Figure 1 (Rivastigmine 02)

A line graph depicting the mean change from baseline in ADAS-cog rating over 26 weeks of treatment. Three groups are compared: 6-12 mg, 1-4 mg, and placebo. The graph shows clinical improvement and decline over time, with error bars representing SEM.*

FDA Label Image

Figure 2 (Rivastigmine 03)

A cumulative percentage graph comparing change from baseline in ADAS-cog scores for Rivastigmine Tartrate treatment groups (6-12 mg and 1-4 mg) versus placebo. The x-axis shows change from baseline, while the y-axis shows cumulative percentage of patients. A table summarizes change in ADAS-cog for each group.*

FDA Label Image

Figure 3 (Rivastigmine 04)

A bar graph showing the CIBIC-Plus Rating distribution as percentages of patients across placebo, 1-4 mg, and 6-12 mg treatment groups. The categories range from Markedly Improved to Markedly Worse, illustrating patient response variation to rivastigmine tartrate and placebo.*

FDA Label Image

Figure 4 (Rivastigmine 05)

A line graph depicting the mean change from baseline ADAS-cog rating over 26 weeks of treatment with Rivastigmine Tartrate at doses of 6-12 mg, 1-4 mg, and placebo. The vertical axis shows mean change with clinical improvement above zero and clinical decline below, while the horizontal axis shows weeks during treatment. Data points include error bars.*

FDA Label Image

Figure 5 (Rivastigmine 06)

A cumulative percentage of patients line chart showing change from baseline in ADAS-cog scores for three treatment groups: 6-12 mg, 1-4 mg, and placebo. X-axis represents change from baseline with markers at -7, -4 points, and no change at 0. The y-axis shows cumulative percentage of patients from 0 to 100. An inset table summarizes mean ADAS-cog score changes for each group at three time points with higher scores for 6-12 mg/day group.*

FDA Label Image

Figure 6 (Rivastigmine 07)

A bar chart compares percentages of patients by CIBIC-Plus Rating categories ranging from markedly improved to markedly worse, grouped by treatment with Placebo, 1-4 mg, and 6-12 mg doses. The vertical axis shows percentage of patients; the horizontal axis lists the CIBIC-Plus Rating categories.*

FDA Label Image

Figure 7 (Rivastigmine 08)

A line graph showing mean change from baseline in ADAS-cog ratings over 24 weeks of treatment comparing Exelon and placebo. The x-axis represents weeks during treatment (0, 8, 16, 24), and the y-axis shows mean change with positive values indicating clinical improvement and negative values indicating clinical decline. Exelon demonstrates increasing improvement, while placebo remains near baseline.*

FDA Label Image

Figure 8 (Rivastigmine 09)

Bar chart comparing patient percentages by ADCS-CGIC rating between Exelon and Placebo groups. Categories include Markedly Improved, Moderately Improved, Minimally Improved, Unchanged, Minimally Worse, Moderately Worse, and Markedly Worse, with differing percentages shown for each treatment group.*

FDA Label Image

Principal Display Panel (1.5 mg Capsule Bottle Label)

Label for Rivastigmine Tartrate Capsules USP 1.5 mg, containing 60 capsules. The label includes the NDC 75834-133-60 and states that each capsule contains Rivastigmine Tartrate equivalent to 1.5 mg Rivastigmine. It is manufactured for Nivagen Pharmaceuticals, Inc., Sacramento, CA, and by Cadila Pharmaceuticals Ltd., India. Storage and dispensing instructions are also provided.*

FDA Label Image

Principal Display Panel (3 mg Capsule Bottle Label)

Label for Rivastigmine Tartrate Capsules USP 3 mg, bottle containing 60 capsules. Label includes NDC 75834-134-60, manufacturing information for Nivagen Pharmaceuticals, Inc. and Cadila Pharmaceuticals Ltd., storage instructions, and dosage reference. The label shows barcode and toll-free customer support number.*

FDA Label Image

Principal Display Panel (4.5 mg Capsule Bottle Label)

Label for Rivastigmine Tartrate Capsules USP 4.5 mg, containing 60 capsules. The label includes NDC 75834-135-60 and states that each capsule contains Rivastigmine Tartrate USP equivalent to 4.5 mg Rivastigmine. It is manufactured for Nivagen Pharmaceuticals, Inc., Sacramento, CA, and by Cadila Pharmaceuticals Ltd., India. Storage instructions and contact information are also provided.*

FDA Label Image

Principal Display Panel (6 mg Capsule Bottle Label)

Packaging label for Rivastigmine Tartrate Capsules USP 6 mg by Nivagen Pharmaceuticals, Inc. The label indicates a bottle containing 60 capsules with storage instructions and manufacturing details, including that it is manufactured by Cadila Pharmaceuticals Ltd., India. The label includes NDC 75834-136-60 and barcodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.